Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.

A novel PET imaging probe detects tumor cell death in vivo and could be useful for personalizing cancer medicine.

A novel class of drugs that target “BET” proteins may have broad utility for treating genetically diverse brain tumors.

An experimental melanoma drug may be beneficial for patients not eligible for targeted therapies.

Measuring levels of an enzyme in head and neck tumors may indicate how the tumor will respond to radiation therapy.